Fate Therapeutics (FATE) Other Non-Current Liabilities (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Other Non-Current Liabilities data on file, last reported at $363000.0 in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 46.96% year-over-year to $363000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $363000.0 (up 46.96% YoY) and the FY2025 annual result came in at $283000.0, down 46.3% from the prior year.
• Other Non-Current Liabilities improved to $363000.0 in Q1 2026, from $283000.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $15.8 million in Q1 2022 to a low of $247000.0 in Q1 2025.
• A 5-year average of $3.0 million and a median of $1.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities plunged 92.24% — and 2024, when it surged 70.76%.
• Tracing FATE's Other Non-Current Liabilities over 5 years: stood at $3.9 million in 2022, then tumbled by 65.14% to $1.3 million in 2023, then plunged by 60.85% to $527000.0 in 2024, then plunged by 46.3% to $283000.0 in 2025, then rose by 28.27% to $363000.0 in 2026.
• The last three Other Non-Current Liabilities figures came in at $363000.0 (Q1 2026), $283000.0 (Q4 2025), and $410000.0 (Q3 2025), per Business Quant data.